Soligenix, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 6, 2026, reporting a net loss of $1,117,525 for the three months ended September 30, 2026.

Key Highlights

  • Net loss for Q3 2026: $1,117,525, compared to $2,530,947 in Q3 2025, according to the filing.
  • Nine-month net loss: $5,929,844 for the nine months ended September 30, 2026, versus $8,184,191 in the same period of 2025.
  • Cash and cash equivalents: $9,023,510 as of September 30, 2026, up from $7,936,153 at December 31, 2025.
  • Shares outstanding: 23,368,754 shares of common stock as of October 30, 2026, up from 10,086,130 at December 31, 2025.
  • At-the-market equity issuance: 13,269,936 shares issued pursuant to the At Market Issuance Sales Agreement during the nine months ended September 30, 2026, raising $6,681,987 gross proceeds.
  • Gain on extinguishment of vendor liabilities: $238,356 recognized in the nine months ended September 30, 2026, with $179,913 recorded in Q3 2026 alone.
  • Accumulated deficit: $250,980,976 as of September 30, 2026.

Soligenix Financial Results for the Three and Nine Months Ended September 30, 2026

According to the filing, Soligenix, Inc. (NASDAQ:SNGX) reported a net loss applicable to common stockholders of $1,117,525, or $(0.05) per basic and diluted share, for the three months ended September 30, 2026. This compares to a net loss of $2,530,947, or $(0.58) per share, for the three months ended September 30, 2025. The weighted average common shares outstanding for Q3 2026 were 22,147,557, compared to 4,329,649 in Q3 2025, reflecting the significant share issuances during the intervening period.

The filing disclosed total operating expenses of $1,375,770 for Q3 2026, consisting of $357,012 in research and development expenses and $1,018,758 in general and administrative expenses. This compares to total operating expenses of $2,580,483 in Q3 2025, which included $1,583,879 in research and development costs. For the nine months ended September 30, 2026, total operating expenses were $6,360,071, down from $8,370,870 in the same prior-year period. The company reported no revenues in either period.

As of September 30, 2026, the registrant reported total assets of $9,464,966 and total shareholders' equity of $6,255,161, compared to total assets of $9,235,521 and total shareholders' equity of $5,292,125 at December 31, 2025. The increase in shareholders' equity was primarily attributed, according to the filing, to proceeds from the At Market Issuance Sales Agreement, partially offset by the net loss for the period. The authorized common stock was increased from 75,000,000 shares at December 31, 2025 to 125,000,000 shares at September 30, 2026, as reported in the balance sheet. Share-based compensation expense of $323,814 was also recorded in the nine months ended September 30, 2026.

What Was Disclosed

Soligenix filed its quarterly report covering the period ended September 30, 2026, disclosing a net loss of $1,117,525 for Q3 2026, cash of $9,023,510, an accumulated deficit of $250,980,976, and significant common stock issuances under its at-the-market sales program.